SCTC21C
Biologic (subtype unspecified)
Evidence outlook · registrational
Multiple Myeloma: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2027-12.
Also in development:Systemic Lupus Erythematosus · Phase 1/2AL Amyloidosis · Phase 3IgA Nephropathy · Phase 1/2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07297329 NCT07297329 · Multiple Myeloma (MM) Registry: NCT07297329 | 3 | Progression free survival (PFS) (Up to approximately 84 months after the First Participant In (FPI)); Minimal residual disease (MRD) negativity rate for participants with CR (Up to approximately 84 months after the FPI) 2027-12 | In progress: results expected 1 Dec 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other CD38 drugs
Daratumumab, Isatuximab, BCD-264, CT-P44, Felzartamab and 7 more. Compare all 13 CD38 drugs
This mechanism is crowded: 13 other tracked programmes target it, 2 of them ahead of this one.
This drug's own stage for AL Amyloidosis: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SCTC21C: this drug | Phase 3 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Anselamimab (Amlypave) | Phase 3 | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| Daratumumab | Phase 3 | Monoclonal antibody | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| Etentamig | Phase 3 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Birtamimab | Discontinued | Monoclonal antibody | Misfolded immunoglobulin light chain (AL amyloid) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow SCTC21C to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.